Date:7/22/2008

ditional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

(1) Avastin(TM), a registered trademark of Genentech, Inc.

(2) Field RW, Smith BJ, Platz CE, Robinson RA, Neuberger JS, Brus CP, et al. Lung cancer histologic type in the Surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004;96:1105--7

(3) Andreas Stang ,Hermann Pohlabeln , Klaus M.Muller ,Ingeborg Jahn , Klaus Giersiepen, Karl-Heinz Jockel Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer (2006) 52 ,29 --36

Contact:

Media& Investors

Ron Kamienchick

T: +1-646- 509 1893

E: investors@rosettagenomics.com

'/>"/>

SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
6. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies